Most patients were diagnosed within the screening programme (71%), but women with Luminal B-like (HER2−), HER2-positive or TNBC more often had clinically detected tumours, compared to those with Luminal A-like tumours (34%, 42% and 37% vs. 25%, respectively) although this was not statistically significant (p = 0.08). The gene discussed is ERBB2; the disease is neoplasm.